Company Overview and News
Dominion Resources changed its name in 2017 (was previously named Dominion Energy (NYSE:D)). It is one of the largest US producers and transporters of energy, with a portfolio of approximately 25,700 megawatts of electric generation, 15,000 miles of natural gas transmission, gathering, storage and distribution pipeline and 6,600 miles of electric transmission and distribution lines.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
EQT Midstream Partners, LP (EQM - Free Report) has recently revealed its intention to build a natural gas pipeline to connect Virginia and North Carolina. The interstate MVP Southgate pipeline project is backed by shipping commitment from SCANA Corporation's (SCG - Free Report) subsidiary PSNC Energy.
WGL Holdings, Inc (WGL - Free Report) announced the receipt of approval from Maryland Public Service Commission for its merger with AltaGas Ltd. (ALA.TO). The merger is valued at $4.5 billion. Subject to approval from the Public Service Commission of District of Columbia, the merger, which was announced on Jan 25, 2017, is expected to be completed by the first half of 2018. Approval Subject to Conditions Maryland Public Service Commission’s approval for the merger of the complementary energy companies is subject to the fulfillment of certain conditions.
Dominion Energy, Inc. (D - Free Report) announced that it has already taken steps to lower its present debt levels. The company decided to sell its non-core assets, issue equity and go ahead with its planned capital reduction to achieve targeted leverage ratio. In February 2018, Dominion Energy borrowed $950 million under a 364-Day Term Loan Agreement that bears interest at a variable rate. In addition, the agreement contains a maximum allowed total debt to total capital ratio of 67.
While broader markets showed increasing weakness on the likelihood of a trade war, utilities did better last week. The Utilities Select Sector SPDR ETF (XLU), which tracks the S&P 500 Utilities Index, slipped more than 2%, and the S&P 500 corrected almost 6%.
Implied volatility in broader markets significantly increased, close to 19%, last week, mainly on the lines of trade war prospects. In comparison, implied volatility in the Utilities Select Sector SPDR ETF (XLU) was 16%, which was higher than its 15-day average volatility.
The merger of SCANA Corporation (SCG - Free Report) with Dominion Energy, Inc. (D - Free Report) has recently been approved by the Georgia Public Service Commission. On February, the electric utility players received consent from the Federal Trade Commission (“FTC”).
SCANA Corporation’s (SCG) present dividend yield of 6.5% is driven by flat dividend growth and its price loss. Its dividend grew 6.0% and 7.0% in 2016 and 2017, respectively. The rise in its dividend yield for 2017 was driven by its price loss. Its dividend is projected to record flat growth in 2018.
SCANA Corp.’s (SCG - Free Report) fourth-quarter 2017 loss of $3.11 per share compared unfavorably with the Zacks Consensus Estimate of earnings of 98 cents. The bottom line also deteriorated from the year-ago quarter’s figure of 87 cents. The decline was caused by higher expenses relating to the abandonment of a new nuclear project. Quarterly operating revenues increased to $1,158 million, up from $1,057 million in the year-ago quarter.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET